Current stock page

Stock Analysis

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis

Taysha Gene Therapies, Inc. (TSHA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

TSHA Stock Analysis Summary

Taysha Gene Therapies, Inc. (TSHA) currently has an AIQ Score of 35/100, indicating a bearish setup. Quality is the strongest factor at 37/100. Momentum is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

TSHA at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$4.10
AIQ Score35/100
Overall ViewBearish
Technical Analysis ConsensusSell
Market Cap$1.67B
P/E Ratio (TTM)-9.53
Forward P/E—
EPS (Q3 FY2026)-$0.10
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.73
Volume2.47M
52-week range$3.46-$7.30
RSI 1444.68
50-Day SMA$4.49
200-Day SMA$5.30
Analyst Price Target—
Next EarningsMar 3, 2027
As of Nov 13, 2026 · Market close

TSHATaysha Gene Therapies, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

BearishEdge 5/10
$4.10−$0.11 (−2.61%)

Latest quote

  • Momentum
    32
  • Value
    —
  • Quality
    37
  • Risk resilience
    37
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

TSHA Stock Analysis Summary

Taysha Gene Therapies, Inc. (TSHA) currently has an AIQ Score of 35/100, indicating a bearish setup. Quality is the strongest factor at 37/100. Momentum is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, TSHA has AIQ Score of 35/100 with Quality base of 37/100 and fading Momentum at 32/100. Wait for component alignment before adding exposure.

Healthcare · -2.61% stock move · TSHA classified in Biotechnology.

Current Evidence

BearishTSHA is in a bearish AIQ regime; Quality is the strongest visible factor at 37/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is TSHA Bullish or Bearish Right Now?

TSHA currently has a bearish overall setup. Quality is the strongest factor at 37/100, while Momentum is weakest at 32/100. The current evidence suggests a bearish setup.

Bull Case
  • - No strong bullish evidence is available in the current snapshot.
Bear Case
  • - Momentum is weak at 32/100.
  • - Risk Resilience is weak at 37/100.
  • - Price is -22.63% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (29 vs 9).

Current Consensus

TSHA's Technical Analysis Consensus is currently Sell, with 9 buy, 8 neutral, and 29 sell votes. TSHA's 14-day RSI is 44.68, which places the stock in a weaker momentum range. TSHA's beta is 1.73, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in TSHA?

The largest recent change in TSHA is Momentum moving up by 4.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+4.0
Quality
+1.0
Risk
+1.0

What Would Change the TSHA Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

TSHA Decision Framework

Public evidence layers, setup checks, and risk context for Taysha Gene Therapies, Inc..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis

Taysha Gene Therapies, Inc. has an AIQ Score of 35/100 in a Bearish regime. Quality is strongest at 37/100. Beta is 1.73, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextTSHA is in a Bearish AIQ regime with score 35/100.
Signal ConflictThe primary conflict is that quality leads at 37/100 while momentum lags at 32/100.
Factor EvidenceMomentum 32/100 · Quality 37/100 · Risk 37/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthFail

Quality is the strongest factor at 37/100.

TimingFail

Momentum is 32/100 and RSI (14) is 44.7.

Regime fitFail

TSHA is in a Bearish regime at 35/100.

Risk controlFail

Risk factor is 37/100 with beta 1.73 and annual volatility 70.69%.

ConflictPass

Current conflict: quality leads at 37/100 while momentum lags at 32/100.

AIQ Score
35/100
Price
$4.10
Beta
1.73
RSI (14)
44.7

TSHA Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

TSHA Fundamentals

TSHA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$39.13M
Free cash flow
-$33.36M
View full TSHA fundamental analysis

TSHA Technical Analysis

TSHA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
44.68
Price vs SMA-50
-8.73%
View full TSHA technical analysis

TSHA Stock Catalysts

Track TSHA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 3, 2027
Analyst target
—
News items
5
View TSHA earnings and stock catalysts

TSHA Dividend Analysis

TSHA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View TSHA dividend history and analysis

TSHA Financial Data

TSHA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.10
Periods
8
View TSHA financials

TSHA Risk Analysis

TSHA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.73
Risk score
37/100
1Y volatility
70.69%
View TSHA risk analysis

TSHA Stock News

TSHA stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read TSHA stock news

TSHA vs Biotechnology Peers

Current peer cohort: TSHA · TVTX · TWST · TYRA · URGN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
TSHA
Current stock
35/100—32/10037/1000.3270.69%Current
TVTX
Travere Therapeutics, Inc.
64/10069/10067/10055/1000.8762.28%TSHA vs TVTX
TWST
Twist Bioscience Corporation
64/10058/10084/10032/1001.9484.18%TSHA vs TWST
TYRA
Tyra Biosciences, Inc.
49/100—27/10045/1000.6567.91%TSHA vs TYRA
URGN
UroGen Pharma Ltd.
53/10064/10040/10040/1000.3961.94%TSHA vs URGN
Pairwise Compare links: TVTX · TWST · TYRA · URGNTSHA vs TVTXTSHA vs TWSTTSHA vs TYRATSHA vs URGNCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a TSHA stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for TSHA: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-9.53
As of Nov 13, 2026
Revenue growth
—
Gross margin
89.17%
Current debt / equity
0.15
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$39.13M
Quarter free cash flow
-$33.36M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
44.68
MACD
-0.06

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
37/100
Beta
1.73
Annual volatility
70.69%
Max drawdown
-49.71%

TSHA Stock FAQ

What is TSHA stock price today?

Taysha Gene Therapies, Inc.'s current stock price is $4.10. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is TSHA bullish or bearish right now?

TSHA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is TSHA's market cap?

TSHA's market cap is $1.67B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is TSHA's current P/E ratio?

TSHA's current P/E ratio is -9.53 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is TSHA's RSI?

TSHA's 14-day RSI is 44.68 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is TSHA above its 50-day and 200-day moving averages?

TSHA is -8.73% from its 50-day SMA and -22.63% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is TSHA's next earnings date?

TSHA's next earnings date is currently listed as Mar 3, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does TSHA pay a dividend?

TSHA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.